Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  West Pharmaceutical Services Inc.    WST

Delayed Quote. Delayed  - 08/28 04:03:19 pm
56.86 USD   -0.40%
07/30 WEST PHARMACEUT : posts 2Q profit
07/30 WEST PHARMACEUT : Announces Second Quarter 2015 Results
07/23 WEST PHARMACEUT : to Host Second Quarter 2015 Conference Call
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data

Warning: Division by zero in /var/www/surperformance/www.zonebourse.com/include/charts/reuters/ReutersTable.inc.php on line 502
Actuals in M $ Estimates in M $
Fiscal Period December 201220132014201520162017
Sales1 2661 3681 4211 4141 528-
Operating income (EBITDA)219248273285336-
Operating profit (EBIT)142162183191228265
Pre-Tax Profit (EBT)109-----
Net income80,7112127133163-
PER ---32,325,8-
EPS ( $)1,151,571,751,762,20-
Dividend per Share ( $)-0,390,410,470,51-
Yield-0,69%0,72%0,83%0,90%-
Announcement Date02/21/2013
12:15pm
02/20/2014
12:00pm
02/19/2015
12:00pm
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201220132014201520162017
Debt------
Finance------
Operating income (EBITDA)219248273285336-
Leverage
(Debt/EBITDA)
------
Capital Expenditure------
Book Value Per Share (BVPS)------
Cash Flow per Share-3,09 $2,51 $3,00 $3,37 $-
Announcement Date02/21/2013
12:15pm
02/20/2014
12:00pm
02/19/2015
12:00pm
---
Balance Sheet Analysis
Assessed data source :
© 2015 Thomson Reuters
Advertisement
Financial Ratios

Size 2015e 2016e
Capitalization 4 094 M$ -
Entreprise Value (EV) - 4 094 M$
Valuation 2015e 2016e
PER (Price / EPS) 32,3x 25,8x
Capitalization / Revenue 2,89x 2,68x
EV / Revenue - -
EV / EBITDA - -
Yield (DPS / Price) 0,83% 0,90%
Price to book (Price / BVPS) - -
Profitability 2015e 2016e
Operating Margin (EBIT / Sales) 13,5% 14,9%
operating Leverage (Delta EBIT / Delta Sales) - 2,43x
Net Margin (Net Profit / Revenue) 9,38% 10,6%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) 13,1% -
Rate of Dividend 26,7% 23,1%
Balance Sheet Analysis 2015e 2016e
CAPEX / Sales   - -
Cash Flow / Sales (Taux d'autofinancement) 15,3% 15,9%
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
EPS & Dividend